70 results about "Lysostaphin" patented technology

Co-administration of a lysostaphin or other anti-staphylococcal agent which cleaves cross-links of peptidoglycans of staphylococci cell walls such as lysostaphin and an antibiotic effective against staphylococci due to antibiotic activity mediated by cell-wall activity is effective against staphylococcal infection, even staphylococci that may be resistant to one or other of lysostaphin or the cell-wall active antibiotic. Co-administration simultaneously suppresses the generation of antibiotic-resistant mutant strains. Effective cell-wall active antibiotics include β-lactams and glycopeptides.

This invention relates to the production of recombinant lysostaphin in a homogenous form through the use of recombinant DNA molecules that express homogenous lysostaphin and host cells transformed with these DNA molecules. This invention also relates to the production of truncated forms of lysostaphin. The resulting lysostaphin preparations can be administered to those at infected or risk for infection by staphylococcal bacteria.

Multi-drug resistant superbugs are a persistent problem in modern health care. This invention provides an antimicrobial endolysin-Lysostaphin triple fusion protein, comprising (1) an endolysin CHAP endopeptidase domain, (2) an endolysin amidase domain, and (3) a Lysostaphin glycyl-glycine endopeptidase domain. The domains are derived from two proteins that show antimicrobial synergy when used in combination. The protein has specificity and exolytic activity for the peptidoglycan cell wall of untreated, live Staphylococcus aureus from many growth phases i.e. stationary, logarithmic and biofilm growth. The recombinant triple fusion protein comprising the three functional antimicrobial domains is designed to be refractory to resistance development.

A portion of the lysostaphin gene of Staphylococcus simulans has been cloned and overexpressed in the cytoplasm of E. coli to yield lysostaphin, in the absence of preprolysostaphin and prolysostaphin, under the transcriptional control of an IPTG-inducible promoter and a ribosome binding site. IPTG induction of the transformed host cells produces intracellular, soluble, mature lysostaphin (27 kDa), in the complete absence of preprolysostaphin and prolysostaphin. The mature lysostaphin so formed dose not require post-translational modification. The mature lysostaphin so formed can be used treat and prevent staphylococcal infections.

Water-soluble polymer conjugates of antimicrobial agents retaining at least a portion of the antimicrobial activity of the agent, pharmaceutical compositions containing the polymer conjugates, and methods for treating microbial infections with the pharmaceutical compositions.

The present invention discloses a lysostaphin compounded preparation. Said preparation comprises bacteria-killing effective quantity of lysostaphin and lysozyme. Said lysostaphin compounded preparation has higher bacteria-killing effect as compared with single lysostaphin, not only has the strong bacteria-killing action for Gram-positive bacterium and Gram-negative bacterium, but also has the good effect for killing the fungi of Candida albicans and red trichophyton, etc. It has high bacteria-killing activity and stability, does not produce drug resistance, and has no toxic side effect.

Lysostaphin is a bacteriocin secreted by S. simulans to kill S. aureus, and has been shown to also be a potent antimicrobial for many antibiotic-resistant strains of S. aureus. By adding a ˜13 amino acid protein transduction domain (PTD) from the HIV-TAT protein to lysostaphin to form lysostaphin-PTD, both extracellular and intracellular forms of S. aureus and MRSA are killed in all (multiple) cell types examined.

The invention provides methods for extraction of fungal (e.g., yeast spp., filamentous fungal spp.) nucleic acid (e.g., DNA, RNA) from a sample (e.g., be human or veterinary clinical or research samples, agricultural samples, agricultural commodity samples, food products, or environmental samples). In some embodiments, the present invention provides enhanced nucleic acid extraction from samples comprising fungal cell(s) wherein enzymatic (e.g., lysostaphin treatment, lyticase treatment) sample treatment is performed in combination with mechanical (e.g., bead beating) sample treatment.

The invention discloses a suppository for treating mammalian endometritis and a preparation method thereof; the suppository comprises the following ingredients by counting total weight of the preparation: 0.001-0.1 percent of lysostaphin, 0.1-10 percent of lysozyme, 0.1-10 percent of sodium alginate tech grade, and 80.0-99.6 percent of polyoxyethylene ascorbyl stearate; by adopting the local administration mode, the mammalian endometritis can be effectively treated, the sterilizing effect is strong, the stability is good; in addition, in the processing process, as the lysozyme and the lysostaphin are packaged by the sodium alginate tech grade, so as to keep the activity of the enzymes in the suppository preparation process, lead the enzymes to be released in utero slowly and achieve better curative effect.

A method of secretory expression of lysostaphin in Escherichia coli at high level, which comprises constructing a expression vector by cloning a sequence encoding a signal peptide which is suitable for secretory expression in Escherichia coli before part or whole gene sequence which encodes mature lysostaphin, and ligating the cloned sequence with a promoter; and transforming Escherichia coli with the expression vector, culturing and fermenting, and then isolating lysostaphin from the supernatant of the fermentation broth. The advantage of secretory expression is that the expression product can exist in the medium in an active form, and thus does not need the process for renaturation of the inclusion body; it is more easily to purify from the supernatant of the fermentation broth with high rate of recovery; and there is less contamination from the host's proteins.

This invention discloses a purification technology for lysostaphin industry, which cultures supernatant purified lysostaphins from sphere bacilli containing the lysostaphin gene. Said method includes ionic exchange and drain chromatograph and needs two days only to process 45L sample, the total recovery rate is 50%, the specific activity is greater than 1000V/mg proteins and the purity is over 90% displayed on the non-recovery SDS-PAGE electrophoresis result.

Topical compositions containing an effective amount of lysostaphin and/or one or more lantibiotics in a pharmaceutically acceptable carrier for topical application. Methods for treating skin or wound infections, including, but not limited to infected abrasions, skin or surface cuts, burns or surgical incisions or decubiti, with the topical compositions are also disclosed.

The invention discloses protamine compounded preparation, a preparation method and application thereof. The protamine compounded preparation of the invention can be singly prepared with the protamine and chitosan, or prepared by compounding one or mixture of over two of glycine, sodium acetate, undecynol monoglyceride, acetic acid, absolute alcohol, lysostaphin, lysozyme, anti-bacterial peptide and sterilized distilled water. The method for preparing the protamine compounded preparation comprises the following steps: accurately weighting each component according to rate in aseptic or clean workshops; putting in clean glass or stainless steel, and uniformly stirring; and sealing in sterile containers. The product not only effectively kills the gram-positive cocci, such as staphyloccocus aureus rosenbach, monilia albican, neisseria gonorrhoeae, streptococcus, anaerobic bacteria, pseudomonas aeruginosa, escherichia coli, pneumococcus, D enterococcus, staphylococcus tetragenus, listeria monocytogenes, stenotrophomonas maltophilia and stomach helicobacter pylori, but also kills the gram-negative bacteria.

The invention discloses a lysostaphic complex enzyme oral cavity disinfectant and a preparation method thereof. The lysostaphic complex enzyme oral cavity disinfectant comprises the following components in parts by mass: 20-40 parts of lysostaphin, 21-41 parts of antibacterial peptide, 21-41 parts of chlorhexidine acetate, 31-42 parts of sorbitol, 21-31 parts of sodium dihydrogen phosphate and 21-30 parts of disodium hydrogen phosphate. The oral cavity disinfectant can be used for treating oral cavity diseases, has the advantages of remarkable curative effect and no alcohol and drug resistance. The invention further discloses a preparation method of the oral cavity disinfectant. The preparation method comprises the following steps: 1) dissolving the lysostaphin, the ntibacterial peptide and the hlorhexidine acetate into distilled water, stirring to completely dissolve the lysostaphin, the ntibacterial peptide and the hlorhexidine acetate; 2) dissolving sorbitol into distilled water, and stirring to completely dissolve the sorbitol; 3) dissolving the sodium dihydrogen phosphate and the disodium hydrogen phosphate into distilled water, and stirring to completely dissolve the sodium dihydrogen phosphate and the disodium hydrogen phosphate; and 4) uniformly mixing solutions obtained in the steps 1), 2) and 3), and then filling the mixed solution. The preparation method has the advantages of simple process and strong operability.

The invention belongs to the technical field of medicine, in particular relating to a freeze-dried powder preparation for curing bovine mastitis. The preparation disclosed in the invention comprises the following components by weigh percent: 0.04-1.5wt% of lysostaphin, 10-72.5wt% of lysozyme, 10-40wt% of retardant, 5-20% of monopotassium phosphate and 10-35% of disodium hydrogen phosphate. When the preparation is poured into the bovine breast, the lysostaphin and lysozyme can maintain favorable stability and sterilization vigor in milk, and flocculent precipitates generated by polymerization of lysostaphin or lysozyme with casein never appear in milk.

The invention discloses a bacteria genome DNA extracting solution in a blood and platelet product and a preparation method and an application method thereof. The bacteria genome DNA extracting solution consists of chelex-100, tween, NP-40, SDS, lysostaphin, a wall-breaking enzyme, a protease K and water. The extracting solution can be effectively used for extracting a bacteria genome DNA with high extraction efficiency. The preparation method and the application method are simple and convenient for operation.

The invention discloses a fragrant disinfectant. The fragrant disinfectant is prepared from the following components in parts by mass: 5-7 parts of citric acid, 3-5 parts of hydrogen peroxide, 5-6 parts of licorice extract, 70-90 parts of distilled water, 4-6 parts of basswood bark, 5-7 parts of parachlorometaxylenol, 4-6 parts of lysostaphin, 2-4 parts of ethyl alcohol, 3-5 parts of chamomile and 1-2 parts of essence. The fragrant disinfectant is suitable for cleaning facial skin, has fragrant smell, has excellent disinfecting and cleaning effects and is free of damage to the facial skin and subcutaneous tissue.

A thermostable composition with antiviral and antimicrobial activity is used as a biologically active component for the production of sanitary and hygienic products, as well as for protection against bacterial and viral infections. In particular, the thermostable composition is a lyophilized powder containing the following components per 1 g of the composition: recombinant interferon gamma human with the activity from 500,000 to 2,000,000 IU/g 0.03 to 0.12 mg; lysostaphin with the activity from 50 to 200 U/g 0.17 to 0.68 mg; methoxy polyethylene glycol 30-150 mg; sodium alginate 10-25 mg; sodium dihydrophosphate dihydrate 120-250 mg; citric acid 35-110 mg and remaining dextran. The thermostable composition can be used as a component of oral hygiene products, toothpastes, sanitary and hygiene articles, a clothes conditioner and condom lubricant and in a number of medicinal products and drugs.